Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Medical Genetics

Specialized Care & Monitoring for PGM1-CDG

At a Glance

PGM1-CDG requires lifelong, coordinated monitoring because it can affect the heart, blood clotting, hormones, growth, liver, and development. A personalized emergency protocol should guide glucose, steroid, cardiac, and coagulation care during illness, fasting, or procedures.

Because PGM1-CDG is a multisystem disorder, managing it requires a “home base” of specialists who communicate with one another. While the metabolic geneticist typically leads the team, the condition’s impact on the heart, blood, hormones, and physical development means that specialized monitoring is a lifelong necessity [1][2].

Your Multidisciplinary Care Team

A comprehensive care team for PGM1-CDG should ideally include:

  • Metabolic Geneticist & Dietitian: Oversees overall diagnosis, D-galactose therapy, and nutritional needs.
  • Cardiologist: Monitors for heart muscle changes and rhythm issues.
  • Endocrinologist: Manages blood sugar, growth, and adrenal health.
  • Hematologist: Monitors blood clotting factors and manages surgical risks.
  • Neurologist: Evaluates for seizures or developmental concerns [3].
  • Support Services: Physical/occupational therapists, speech/feeding specialists (especially for infants with cleft palate), and social workers as clinically indicated.

Cardiac Surveillance Schedule

The heart is one of the most critical areas for monitoring because cardiomyopathy (weakening of the heart muscle) can develop even when other symptoms are well-controlled by treatment [4][5].

  • Surveillance Schedule: Cardiac monitoring must be individualized based on your age, symptoms, prior imaging, and clinical history. Current broad CDG proposals suggest a schedule such as annual check-ups to age 5, every 2-3 years through childhood, and every 5 years in adulthood [6]. However, every five years is not a safe default for every adult. You must follow your specialist-directed intervals, and any abnormal findings require more frequent follow-up.
  • Note: Any symptoms like fainting, chest pain, or palpitations should trigger an immediate evaluation, regardless of the schedule.

Coagulation and Blood Health

Abnormalities in blood clotting are extremely common, affecting about 67% of reported patients with available data [7]. Patients face a paradoxical risk: they can experience both bleeding and clotting problems.

  • Monitoring Panel: Your hematologist will guide your screening. This often involves checking a coagulation panel to assess risks. These tests are individualized, as results can be affected by acute illness, age, or liver disease.
    • PT/INR and aPTT: Tests that measure how long it takes blood to clot (assessing bleeding risk).
    • Antithrombin and Proteins C and S: Natural proteins in the blood that prevent excessive clotting. A deficiency (especially in antithrombin) increases the risk of thrombosis [7][8].
  • Important Caveat: A low antithrombin level does not automatically mean you need blood-thinning medication (anticoagulation), nor does regular testing directly prevent a clot. Instead, this monitoring informs procedural planning. Before any surgery or invasive dental work, it is vital to have these levels checked so your team can create a safety plan [9].

Endocrine and Growth Monitoring

The “low energy” aspect of PGM1-CDG can mimic other hormonal problems.

  • Adrenal Health: If you or your child have recurrent episodes of ketotic hypoglycemia (low blood sugar with high ketones), doctors may perform an ACTH stimulation test. This checks if the brain and adrenal glands are properly communicating to produce the stress hormone cortisol [10][2].
  • Growth Factors: Regular tracking of growth velocity is essential. Doctors may check IGF-1 (a marker for growth hormone levels) to determine if specialized hormone support is necessary [10][11].

Liver Health

While D-galactose often improves liver enzymes (ALT/AST), the liver still requires regular monitoring. In some cases, patients have shown signs of hepatic fibrosis (scarring) or steatosis (fatty liver). Your doctor may recommend periodic imaging or liver elastography (a specialized ultrasound that checks for liver stiffness and scarring) [8][12].

The Importance of an Emergency Protocol

Because illness or fasting can trigger a metabolic crisis, every patient must have a written Emergency Protocol. This letter should be a patient-specific algorithm completed by your clinician. It must detail:

  1. IV Glucose Instructions: Clear criteria for urgent IV dextrose when oral intake fails, when glucose or ketone values meet your specific action thresholds, or when you are clinically unstable.
  2. Endocrine Plan: Stress-dosing steroids, if applicable.
  3. Cardiac and Coagulation Risks: Clear alerts for the emergency team regarding cardiomyopathy and bleeding/clotting risks [10][1].

Common questions in this guide

How often should the heart be checked in PGM1-CDG?
The schedule depends on age, symptoms, prior heart imaging, and clinical history. Broad proposals may suggest yearly checks through age 5, every 2 to 3 years during childhood, and every 5 years in adulthood, but your specialist may recommend a different interval. Fainting, chest pain, or palpitations require prompt medical evaluation regardless of the routine schedule.
What blood tests may be needed before surgery or dental work with PGM1-CDG?
A hematologist may recommend a personalized coagulation evaluation, which can include PT/INR and aPTT to assess clotting time, along with antithrombin and proteins C and S. The timing and exact tests depend on the person and procedure. A low antithrombin level does not automatically mean that blood-thinning medicine is needed.
Can PGM1-CDG cause both bleeding and blood clots?
Yes. People with PGM1-CDG may have abnormalities that increase bleeding risk as well as deficiencies in natural anti-clotting proteins, especially antithrombin, that can increase the risk of a blood clot. New unusual bleeding or symptoms such as a swollen calf should be discussed urgently with a medical professional.
What should an emergency protocol for PGM1-CDG include?
A written, patient-specific protocol should explain when urgent intravenous dextrose is needed if oral intake fails, glucose or ketone values reach the person's action thresholds, or the person is unstable. It should also state whether stress-dose steroids apply and alert emergency clinicians to cardiomyopathy and bleeding or clotting risks.
What hormone and growth monitoring may be needed in PGM1-CDG?
Recurrent ketotic hypoglycemia may lead a clinician to order an ACTH stimulation test to assess the body's cortisol response. Growth velocity should be tracked, and IGF-1 testing or hormone support may be considered if growth slows. Testing and treatment should be individualized by the endocrine and metabolic teams.
Why does PGM1-CDG require ongoing liver monitoring?
D-galactose therapy may improve liver enzyme levels such as ALT and AST, but some people can still develop liver scarring or fatty liver. A clinician may recommend periodic imaging or liver elastography, an ultrasound-based test that assesses liver stiffness and scarring.
Who coordinates the specialists involved in PGM1-CDG care?
The metabolic geneticist commonly serves as the central clinical lead, working with a metabolic dietitian and specialists such as cardiology, endocrinology, hematology, and neurology. Families can ask the team to identify one point person who coordinates appointments, results, and emergency planning.

Get notified when new evidence is published on PGM1-CDG.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and management.

    Altassan R, Radenkovic S, Edmondson AC, et al.

    Journal of inherited metabolic disease 2021; (44(1)):148-163 doi:10.1002/jimd.12286.

    PMID: 32681750
  2. 2

    Phosphoglucomutase-1 deficiency: Early presentation, metabolic management and detection in neonatal blood spots.

    Conte F, Morava E, Bakar NA, et al.

    Molecular genetics and metabolism 2020; (131(1-2)):135-146 doi:10.1016/j.ymgme.2020.08.003.

    PMID: 33342467
  3. 3

    Central nervous involvement is common in PGM1-CDG.

    Radenkovic S, Witters P, Morava E

    Molecular genetics and metabolism 2018; (125(3)):200-204 doi:10.1016/j.ymgme.2018.08.008.

    PMID: 30262252
  4. 4

    Successful heart transplantation in an infant with phosphoglucomutase 1 deficiency (PGM1-CDG).

    Altassan R, Albert-Brotons DC, Alowain M, et al.

    JIMD reports 2023; (64(2)):123-128 doi:10.1002/jmd2.12350.

    PMID: 36873091
  5. 5

    AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a mouse model of phosphoglucomutase 1 deficiency (PGM1-CDG).

    Balakrishnan B, Altassan R, Budhraja R, et al.

    Translational research : the journal of laboratory and clinical medicine 2023; (257()):1-14 doi:10.1016/j.trsl.2023.01.004.

    PMID: 36709920
  6. 6

    Cardiomyopathy, an uncommon phenotype of congenital disorders of glycosylation: Recommendations for baseline screening and follow-up evaluation.

    Zemet R, Hope KD, Edmondson AC, et al.

    Molecular genetics and metabolism 2024; (142(4)):108513 doi:10.1016/j.ymgme.2024.108513.

    PMID: 38917675
  7. 7

    Coagulation abnormalities and vascular complications are common in PGM1-CDG.

    Radenkovic S, Bleukx S, Engelhardt N, et al.

    Molecular genetics and metabolism 2024; (142(4)):108530 doi:10.1016/j.ymgme.2024.108530.

    PMID: 38968673
  8. 8

    Oral D-galactose supplementation in PGM1-CDG.

    Wong SY, Gadomski T, van Scherpenzeel M, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(11)):1226-1235 doi:10.1038/gim.2017.41.

    PMID: 28617415
  9. 9

    Pregnancy in a Woman with PGM1-CDG: Longitudinal Metabolic Follow-up During a Lactose-Supported Diet.

    Akyüzlüer Güneş MS, Koç Yekedüz M, Sürücü Kara İ, et al.

    Journal of clinical research in pediatric endocrinology 2026; doi:10.4274/jcrpe.galenos.2026.2026-7-12.

    PMID: 42969211
  10. 10

    Phosphoglucomutase-1 deficiency: Intrafamilial clinical variability and common secondary adrenal insufficiency.

    Loewenthal N, Haim A, Parvari R, Hershkovitz E

    American journal of medical genetics. Part A 2015; (167A(12)):3139-43 doi:10.1002/ajmg.a.37294.

    PMID: 26768186
  11. 11

    PGM1 deficiency diagnosed during an endocrine work-up of low IGF-1 mediated growth failure.

    Zeevaert R, Scalais E, Muino Mosquera L, et al.

    Acta clinica Belgica 2016; (71(6)):435-437 doi:10.1080/17843286.2016.1142043.

    PMID: 27351072
  12. 12

    Novel PGM1 Mutation in Congenital Disorder of Glycosylation Type 1T: A Case Report of Liver Failure and Myopathy.

    Al-Ahmari AA

    The American journal of case reports 2025; (26()):e948797 doi:10.12659/AJCR.948797.

    PMID: 41182978

This page is for informational purposes only and does not constitute medical advice. PGM1-CDG monitoring, testing, treatment, and emergency instructions should be individualized by your metabolic genetics team.